2025-524987-39-00招募中1 期
A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma
Aclaris Therapeutics Inc.2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2026年3月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Aclaris Lead Clinical Development Physician
Scientific
Aclaris Therapeutics Inc.
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MR-L45 in Healthy AdultsAutosomal Dominant Polycystic Kidney Disease2025-524899-40-00Mironid Limited72
招募中
1 期
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors2023-508808-38-00CDR-Life AG49
招募中
1 期
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid TumorsCervical squamous cell carcinomaBreast CancerBladder Cancer2024-516870-31-00Merck Sharp & Dohme LLC14
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113
招募中
1 期
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies2024-511453-22-00Kumquat Biosciences Inc.112